CBF-AML is characterized by recurrent cytogenetic abnormalities, specifically t (8,21)(q22;q22.1) and inv (16)(p13.1q22)/t (16,16)(p13.1;q22), which generate RUNX1::RUNX1T1 or CBFB::MYH11 fusion transcripts, respectively. This evidence concerns the gene CBFB and acute myeloid leukemia.